U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06855069) titled 'HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer' on Feb. 25.
Brief Summary: This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Study Start Date: March 07
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Intervention:
DRUG: HS-20089
HS-20089 dose 1
DRUG: Paclitaxel
Paclitaxel dose 2
DRUG: Doxorubicin
Doxorubicin dose 3
DRUG: Topotecan
Topotecan dose 4
Recruitment Status: NOT_YET_RECRUITING...